Acuta Capital Partners’s Alkermes ALKS Stock Holding History

Acuta Capital Partners’s Portfolio ALKS Stock Details ALKS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-126,500	Closed	-$3.54M	–	41
2023 Q3	$3.54M	Buy	126,500 +81,811	+183%	+$2.4M	2.37%	16
2023 Q2	$1.4M	Buy	44,689 +13,000	+41%	+$394K	0.95%	24
2023 Q1	$893K	Buy	+31,689	New	+$863K	0.66%	23

Other funds holding ALKS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HJGA

Hardman Johnston Global Advisors Stamford, Connecticut $2.1B AUM 41.89% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Acuta Capital Partners's ALKS Position: Q4 2023 in Review

Acuta Capital Partners sold out of Alkermes (ALKS) in Q4 2023, closing a stake of 126,500 shares — an estimated $3.54M sold.

Acuta Capital Partners first reported a position in ALKS in Q1 2023 and held it in 3 quarters. The position peaked at $3.54M in Q3 2023. 301 funds tracked by Wall St. Rank hold ALKS as of Q4 2023.

Acuta Capital Partners reported no remaining Alkermes position as of Q4 2023 after selling out during the quarter.
Acuta Capital Partners sold 126,500 Alkermes shares in Q4 2023, an estimated $3.54M.
Acuta Capital Partners first reported a position in Alkermes in Q1 2023 and held it in 3 quarters.
Acuta Capital Partners's Alkermes position peaked at $3.54M in Q3 2023.
301 funds tracked by Wall St. Rank held Alkermes as of Q4 2023.

Based on Acuta Capital Partners's 13F filing for Q4 2023, filed 14 Feb 2024.